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Background: Electronic prescription registers provide a vast data source for pharmacoepidemiological research.
Prescriptions as such are not suitable for all research purposes; e.g., studying concurrent use of different drugs or
adverse drug events during current use. For those purposes, data on dispensed prescriptions needs to be
transformed to periods of drug use.
Methods: We used 3,828,292 dispensed prescriptions claimed between 1 January 2002 and 31 December 2009 for
28,093 persons with Alzheimer’s disease. Examples of drug use histories are presented to discuss different aspects
that should be noticed when using register-based data consisting of drug purchases.
Results: There is no simple method for correctly transforming dispensed prescriptions to periods of drug use that is
usable for all drugs and drug users. Fixed assumptions of daily dose (in defined daily doses, tablets or other units)
and fixed time windows should be used with caution and adjusted for different drug use patterns.
Conclusions: We recommend that when transforming prescription drug purchases to drug use periods personal
dose, purchasing pattern and other behavioral differences between patients should be taken into account.
Keywords: Prescription register, Modeling, Drug utilization, PharmacoepidemiologyIntroduction
Electronic prescription registers have been used in medical
research since the early 1990’s [1-4] although the history of
prescription databases began much earlier [5,6]. Nationwide
prescription data from Nordic countries have generated
several publications; e.g., a recent review lists 515 studies
published between 2005 and 2010 [7]. At first, prescription
registers were mainly used to collect drug use statistics
and drug utilization data, mostly to determine adherence
[1,8,9]. The possibility of linking a person’s prescriptions
and outcome data with hospital discharge or death reg-
isters, for example, have enabled researchers to conduct
nationwide studies to measure effectiveness and adverse
events, such as morbidity or mortality.
Prescription registers contain information on the pre-
scriber, patient, drug (ATC classification, package informa-
tion), time of dispensing and possible dosage instructions in* Correspondence: antti.tanskanen@ki.se
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,
Sweden
2National Institute for Health and Welfare, Helsinki, Finland
Full list of author information is available at the end of the article
© 2014 Tanskanen et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.free text format (e.g., details of Nordic data [10]). Prescrip-
tion data are not, however, directly useful for many research
questions; e.g., in the study of outcomes related to current
drug use, exposure status at the index date of the outcome
must be determined. Furthermore, dosages must be defined
if the dose–response relationship is a matter of interest.
Both exposure periods and dosages can be estimated from
prescription data by modeling individual drug use.
Prescription registers contain dosage information via
Defined Daily Dose (DDD), which is the assumed average
maintenance dose per day for a drug that is used for its
main indication in adults [11]. The DDD is an effective
rough measure for comparing the consumption of dif-
ferent drugs. However, the assumption of one DDD as a
standard dose can be erroneous, as DDD is the dose
used in monotherapy for a specific indication. Moreover,
the actual dosage may vary widely between different
indications or patient groups, such as children and older
people. The DDD is often a compromise of doses used in
several countries [11]. However, DDD may be used as a
universal measure of the purchased amount of drug, rathertral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Eventually, the purchased amount of drug, which is
often reported as DDD in prescription register data, can
be translated into other units (like milligrams) by using
the ATC-DDD index. Thus, DDD is a practical measure
to use when translating data from prescription registers
to periods of drug use, if its limitations are appropriately
accounted for.
The number of dispensed units, such as tablets, can also
be used to estimate drug use periods. The main problem
with this information is that the number of tablets taken
per day may vary between different strengths of the same
drug. There may also be large variations in dose per day
for different patients using the same drug. In contrast,
DDD is independent of packet size and strength of the
drug (e.g., ten 10 mg tablets are equal to five 20 mg tablets
of the same formulation).
The aims of this paper is to present some perspectives
on how to translate prescription data to periods of drug
use, and to introduce critical elements that should be
considered when constructing drug use periods from
prescription register data.Material and methods
Data source
The examples in this paper derive from the MEDALZ-
2005 cohort prescription data, which included all
community-dwelling persons with a verified diagnosis of
Alzheimer’s disease residing in Finland on 31 December
2005 (n =28,093) [12] . Persons with Alzheimer’s disease
have been identified from special reimbursement register.
This register includes data on entitlement to special re-
imbursement due to several chronic diseases (includ-
ing Alzheimer’s disease, asthma and diabetes) that have
been diagnosed by a physician. Data of MEDALZ-2005
cohort has been linked to several nationwide registers
including prescription register, special reimbursement
register, hospital discharge register (Hilmo) and regis-
ter of care at social institutions. Altogether 3,828,292
prescriptions were claimed between 1 January 2002 and
31 December 2009 (on average 136 prescriptions per per-
son). In Finland, drugs may be dispensed for a maximum
of three months’ treatment period at a time. The Finnish
Prescription Register does not cover non-reimbursable
drugs, over-the-counter drugs or drugs used in hospitals
and nursing homes.Calculations
DDD per day values were calculated by sliding temporal
averages to smoothen variations in purchase histories.
This approach takes into account potential changes in
the patient’s personal drug stock at the time of the
next prescription purchase. For each purchase, a slidingtemporal average for dose (DDDAVGi) was calculated as
follows:
DDDAVG i ¼ DDDi−1 þ 4DDDi þ DDDiþ1Ti−1 þ 4Ti þ Tiþ1
where DDDi is the DDD amount purchased at time i,
and Ti is the amount of days between purchase i and i + 1.
We weighed consecutive drug purchases and times with
weights 1, 4 and 1 for i-1, i and i + 1, respectively. For each
person’s first purchase of each ATC-class, drug and time
weights were 5 for i, 1 for i + 1, and for last purchase 1 for
i-1 and 5 for i. For the last purchase i Ti is calculated from
the previous purchase assuming the same DDD per day
value as previous purchase, Ti = DDDi/(DDDi-1/Ti-1). This
assumption that dose does not change is used for conveni-
ence. The weights were selected to give moderate smooth-
ening over time. Average DDDs per day were calculated
only when there were at least three purchases of the same
ATC code for one person. Hospital days were excluded
(i.e., days in hospital have been subtracted from T), as
drugs are provided by the hospital during hospital stays,
and this information is not entered in the prescription
register. These calculations were made for all drugs
used by the cohort and recorded in the prescription
register.
We compare three methods for converting purchases
to drug use periods: Firstly one DDD per day rule, in
which persons are assumed to take drug one DDD per
day, i.e. a package containing 30 DDD equivalents lasts
30 days [13]. Secondly we describe one tablet per day
rule, which assumes that drug is consumed 1 tablet
(unit) per day [14,15]. Thus, one package of 30 tablets
would last 30 days. Thirdly, fixed time window methods
(time since last purchase, calendar time or grace periods)
are described. Fixed time windows may define a time
period from the last purchase when the next purchase
must take place if drug use is continuous [16]. For ex-
ample, the next purchase must take place within 90 days
from the last purchase or else drug use is considered
discontinued. Fixed time windows are also used in terms
of calendar time, where current drug use is determined
by purchases taking place during fixed calendar time
periods, for example in three months [17]. In addition,
fixed time windows are used as grace periods, when fixed
time is added to drug use time calculated from purchased
amount and/or dose [18].
Results and discussion
One DDD per day rule
The average DDD per day typically varied between 0.5
and 2 for many of the commonly used drugs in the
MEDALZ-2005 data. Some drugs were used at a lower
dose; e.g., antipsychotics (ATC class N05A), where mean
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(N of purchases = 42,950; S.D. 0.44) and for risperidone
(N05AX08) 0.21 (N of purchases = 53,864; S.D. 0.39).
These drugs were widely used among MEDALZ-2005
participants with AD, with over 40,000 purchases of
both drugs. In such cases, the assumption of one DDD
per day would clearly underestimate the length of expos-
ure period and lead to an erroneous conclusion of several
short recurrent drug use periods for most patients.
In MEDALZ-2005 data, temazepam (N05CD07) and
zopiclone (N05CF01) typically averaged 1 DDD per day;
1.10 (N = 43,664; S.D. 2.07) and 1.18 (N = 59,728; S.D.
1.86), respectively. In both cases, however, the standard
deviation reveals a high variation in DDD per day values.
Figure 1 describes distribution of average DDD per day
doses for temazepam used by MEDALZ-2005 participants.
There are two clusters of DDD values; one at 0.5 DDDs
per day and the other at 1.0 DDDs per day. Some patients
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Figure 1 DDDAVG distribution of temazepam (N05CD07), two most coDDDs per day and, thus, distribution spreads to higher
values and the average is greater than 1 DDD. Assump-
tions such as 1 DDD per day, or any other fixed dose
assumption, may lead to biased estimates and only in-
dividually calculated dose estimates will be appropriate
in such cases.
Figure 2 illustrates a purchase history for a patient
using lactulose (A06AD11, laxative) over 2,000 days
(about 5.5 years). The purchased amount is 100 DDDs
at one time until the end of follow-up, when 200 DDDs
are purchased at a time. DDD per day varies between 4
and 6, except in the middle of the drug use period (after
1000 days), when it increases up to 10 DDDs. The time
between purchases was typically between 20–30 days.
This example presents an unusually large variation in
dosage, possibly due to patient’s condition, and the as-
sumption of 1 DDD per day is clearly not valid. Very
high values for DDDs per day typically result from refills
that occur shortly after a previous purchase, and are not4.0 6.0 8.0
erage DDD






















































Figure 2 A case history with a high number of purchases (n = 101) and high DDD per day dose (4–6) of lactulose (A06AD11), over
six years.
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many drugs are below one DDD per day due to ad-
vanced ages, high prevalence of renal dysfunction and
several comorbidities and concomitant use of multiple
drugs for same disease.
Use of package size and strength – the one tablet per
day rule
The prescribed number of tablets per day is a useful
measure of drug exposure, but this information is diffi-
cult to extract from prescription registers, especially
when the written dosage instructions are complicated or
missing. In Nordic countries, Nordic Article numbers
(vnr-numbers) are used to identify the drug package (i.e.,
drug substance, manufacturer, number of drug units,
strength and dosage form) [19]. Almost all drugs are
sold in different package sizes, for example 30 and 100
tablets representing treatment periods of one and three
months, respectively. Drugs that are mainly used occa-
sionally, for example non-steroidal anti-inflammatory
drugs (NSAIDs), are often marketed with various pack-
age sizes.
When package information is available and coded with
package identification numbers (such as vnr-numbers),such information can be utilized in large datasets to
determine typical refill lengths for each package. Refill
length refers to the interval between two purchases.
Refill length describes how long the package lasts and,
thus, the typical daily dose. Typical refill lengths for each
package are useful when there is not enough information
to evaluate drug use period like when a person who has
purchased the drug only once during the follow-up.
Douglas and Smeeth used package information in their
study to fill gaps in purchase information [20].
Quetiapine (N05AH04) is presented as an example of
different drug use patterns with different drug strengths
(Figure 3A and B). This example includes quetiapine in
25 mg tablets (Vnr 075533, 25 mg, 100 tablets) and
200 mg tablets (Vnr 075551, quetiapine 200 mg, 100
tablets). In Figure 3A, peaks describing the most com-
mon refill lengths of quetiapine 25 mg tablets are 20, 25,
33, 50 or 100 days per package. The peak at 20 days in-
dicates that a group of individuals purchased 100 tablets
between 20 days interval and, thus, used 5 tablets a day.
Quetiapine 25 mg tablets are therefore used at a rate of
one to five tablets per day in this cohort. Long refill
lengths indicate some restarts in treatment, or possible
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Figure 3 Distribution of refill time lengths for a single package of 25 mg quetiapine, package size 100 tablets, Nordic article number
075533 in (A), and for 200 mg quetiapine, package size 100 tablets, Nordic article number 075551 in (B).
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milligram tablets (Figure 3B) are typically used at a rate
of two tablets per day (peak at 50 days), and this dosage
is equivalent to one DDD per day. The 200 mg quetia-
pine product is infrequently used within the MEDALZ-
2005 cohort (61 purchases), compared to the 25 mg
product (3,815 purchases). The distributions of refill
times presented here are limited to this population, and
are not transferrable to other populations, especially
younger individuals who may have a different indication
of use and, consequently, a different dose. Polypharmacy
may also explain low doses in some cases. Examples
above show how difficult it is to use any exact number
of tablets per day rules to estimate drug use periods.
Regularity of purchases
Patients display varying patterns of purchases from the
pharmacy, as some visit pharmacy at regular intervals
and the same amount is dispensed each time. Often this
idiosyncratic style is stable and could be used in model-
ing periods of drug use. Figure 4A presents a patient
who bought 60 DDDs of metoprolol (C07AB02, beta
blocker), at regular time intervals of 90–100 days. Hardly
any stockpiling could be expected with this purchase
history, and the dosage is expected to be between 0.6
and 0.7 DDDs per day. There are no signs of titration
periods in this purchase history example.
An irregular purchase history of warfarin, an anti-
coagulant, shows how purchases can be clustered in
time (Figure 4B). At the beginning, the patient purchases
packages containing 40 DDDs of warfarin for almost
four years, with 21–184 days between purchases. In this
example, the last two purchases of warfarin included 67DDDs each, which may indicate a dosage change. Some
stockpiling may have also occurred between days 370–
560 (i.e., frequent purchases of warfarin). This patient
had probably used warfarin as prescribed, but with rigid
rules for fixed amount of DDD per day (here the average
is 0.45 DDD per day), or fixed amounts of tablets per
day, the patient would have periods of both high and
low adherence.
Stockpiling
Stockpiling is a fairly common phenomenon with drug
purchases. Sometimes stock may be large, especially
during holiday seasons and periods of travel. Al-
though reimbursement regulations generally try to limit
stockpiling, such regulations may also induce seasonal
variation; e.g., by exceeding the annual excess costs at
the end of the calendar year. During week 51 before
Christmas in 2007, for example, 28,093 cases from the
MEDALZ-2005 data had purchased 769,501 DDDs of
drugs, whereas the second week in January of 2008, only
497,626 DDDs were purchased. Both weeks had the
same amount of working days and thus, equal access to
pharmacies. Thus, stockpiling helps to explain at least
some irregularity in purchases.
Table 1 shows a purchase history for combination of
losartan and diuretic (C09DA01, antihypertensive drug).
A patient uses losartan with 1.0 DDD per day calculated
from 27 purchases, over 2,747 days (ca. 7.5 years), assum-
ing no stock in the beginning or at the end of study
period. At day 271, the patient bought two packets of drug
and slowly used the stock so that on day 1,675 (ca.
4.6 years) the stock was negative. This indicates the pres-





























































































































Figure 4 Two different purchase patterns of metoprolol (C07AB02); a regular in (A) and an irregular in (B) with variations in both
purchased amount and intervals between purchases.
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Because the cumulative stock varied around zero, between
−15 and 15 DDD during the rest of follow-up, it likely that
there were still some tablets left by day 1,675, and possibly
some stock at the beginning of the follow-up.
Changing dosage
In long-term use, drug dosage may vary due to disease
progression, changes in lifestyle and nutritional factors
(e.g., with lipid modifying agents), or drug tolerance (e.g.,
with strong opioids). Changes may include gradually
increasing dose, or medically ordered changes in doses
according to clinical testing (e.g., with warfarin and an-
tidiabetics). The reasons for such changes are difficult
to assess from the prescription register. In these cases,
a particular dose at a specific time point may not be
equal to the average dose over the entire period of drug
use. To overcome this problem, dosage should be estimated
over time with local, limited time windows.
Titration of the appropriate drug dose is sometimes
required at the beginning of treatment for certain drugs,
and often there is a standard procedure on how to in-
crease the dosage to the effective level. For example, theuse of the anti-dementia drug donepezil (N06DA02)
typically begins with 5 mg per day, or even a lower dos-
age of 2.5 mg per day for the first few days or one week.
Within two to six months, the dose can be increased to
the recommended daily dose of 10 mg per day, if the
drug is well tolerated by the patient.
Figure 5 illustrates an individual’s drug use period of
oxycodone (N02AA05, opioid). In this example, oxycodone
was used for over three years and the dosage dramatically
increased after the second year of use.
Varying amounts of drug purchased per time
One reason for variations in refill time lengths is due to
differing amounts of drug obtained per purchased; e.g.,
changes in package size, the number of packages and/or
strength. Smaller packages may be bought at the beginning
of treatment, when it is not certain whether the drug is
suitable or even necessary for longer periods. The strength
of a drug unit can initially be smaller and when the
optimal dose has been found and it may be increased to
decrease the amount of tablets taken per day. In addition,
the financial situation of the patient may have an impact
on the amount of drug purchased each time. Finally,











with 1.0 DDD per







0 0 98,00 98
84 84 98,00 98 14 14
187 103 98,00 98 −5 9
271 84 196,00 196 112 121
364 93 98,00 98 5 127
435 71 98,00 98 27 154
539 104 98,00 98 −6 148
679 140 98,00 98 −42 106
746 67 98,00 98 31 137
868 122 98,00 98 −24 113
967 99 98,00 98 −1 112
1078 111 98,00 98 −13 99
1149 71 98,00 98 27 126
1359 210 98,00 98 −112 14
1400 41 98,00 98 57 72
1514 114 98,00 98 −16 56
1675 161 98,00 98 −63 −7
1774 99 98,00 98 −1 −8
1879 105 98,00 98 −7 −15
1963 84 98,00 98 14 −1
2061 98 98,00 98 0 −1
2145 84 98,00 98 14 13
2271 126 98,00 98 −28 −15
2341 70 98,00 98 28 14
2439 98 98,00 98 0 14
2536 97 98,00 98 1 15
2649 113 98,00 98 −15 0
2747 98 98,00 98 0 0
In this example, combination of losartan and diuretic is used on average 1.0 DDDs per day (i.e., 1 tablet per day).
The purchase on day 271 created a stock that remained until the purchase on day 1,359. Otherwise this patient had quite a regular purchase pattern.
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as they are designed to reduce both stockpiling and limit
the amount purchased at one time.
Figure 6 describes a purchase history of escitalopram
(N06AB10), a selective serotonin uptake inhibitor (SSRI).
For the first two years, the patient mainly bought 50
DDDs per purchase, and then began purchasing 150
DDDs per purchase. The average DDD per day remained
unchanged, but the time between purchases tripled
because a larger amount was purchased at a time.
Such purchase histories are complicated and difficult
to analyze with confidence. For example, when trying to
define the current drug use with the rule whether a
purchase occurred during the last 90 days in Figure 6,a person would be categorized as a continuous drug
user for the first two years, but subsequently the refill
time length increased to 150 days, which suggests
90 days of drug use and 60 days of non-use. Longer
fixed times such as “bought in the last 180 days” would
also lead to miscalculations, as the previously ended
period of drug use would be classified as current drug use.
In contrast, shorter fixed times would omit the actual
current usage [18]. When drugs can be purchased
in different package sizes and strengths, there is no
appropriate fixed value for the refill time length. Thus,
individual or package-based calculations are required.
It is also possible that ignoring differences in package

















































Figure 6 The amount of DDD purchased; escitalopram (N06AB10). Refill time length between purchases increased while the dosage

























































Figure 5 Increasing dosage and package size of oxycodone (N02AA05) in long-term use. The dosage is three-fold higher than the initial
value by the end of the follow-up after hospital stays marked on timeline.
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come may be more inclined to purchase drugs in smaller
packages (i.e., a smaller charge at a time) than persons
with middle or higher income.
Other sources of drugs
The coverage of prescription registers varies between
countries. Thus, patients may get their drugs from other
sources than pharmacies, which may not be visible in
the prescription register data. In Finland, the drugs used
during hospital stays are provided by the hospital. The
same applies to several public nursing homes, but now-
adays in diminishing proportions. Gaps in the prescription
register data may reflect remission or, more likely, long
stays in hospital and/or nursing home (Figure 7). Thus,
additional information on hospital stays, and time in a
nursing home, improves the estimation of true drug use
periods. Also, some drugs are available over the counter,
in smaller packages or lower strengths, which may bias
dosage counts if some of the refills are not readily access-
ible through registers. Physicians may also give “sample
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Figure 7 An individual’s purchase history for about six years, which d
stays between days 679–719, 1506–1574 and 2113–2250 (marked with grey
resides in nursing home, so no information on drug use is available in themaking the exact starting date unknown. Purchasing
drugs while traveling abroad may also lead to an
underestimation of drug use. Price differences between
countries and variations in the availability of some
generic drugs may encourage the purchase of drugs
while traveling.
In Finland, some drugs are available over the counter
in smaller package sizes and lower strengths, whereas
larger packages and higher strengths are only dispensed
with a prescription, and typically only these prescription-
based packages are reimbursed. Reimbursement and
regulatory decisions may change over time, and they
are often related to the prices of drugs. Changes in
both reimbursement schemes and over-the-counter
status introduce variabilities that must be considered
when using prescription registers. Such changes may
introduce anomalies in the prescription histories, which
must be recognized.
Conclusions
The utilization of prescription register data in pharma-
coepidemiological studies requires a simulation of drug00 2000
 20 :  A06AD11, lactulose
 19 :  B01AA03, warfarin
 18 :  C01AA05, digoxin
 17 :  C01DA02, glyseryl trinitrate
 16 :  C01DA14, isosorbide mononitrate
 15 :  C07AB02, metoprolol
 14 :  C07AB04, acebutolol
 13 :  C08CA01, amlodipine
 12 :  D07XC01, betamethasone
 11 :  J01CA04, amoxicillin
 10 :  J01CA08, pivmecillinam
   9 :  J01DB01, cefalexin
   8 :  J01EA01, trimethoprim
   7 :  M01AC06, meloxicam
   6 :  M01AH01, celecoxib
   5 :  M05BB03, alendronic acid and colecalciferol
   4 :  N05AD01, haloperidol
   3 :  N05CD07, temazepan
   2 :  N06AB04, citalopram
   1 :  N06DX01, memantine
Drug no. :   ATC, drug name
escribes the purchase of 20 different drugs. Note the long hospital
bars). After day 2250, this person has not collected any drugs and
prescription register.
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using such information is to establish how drugs are
dispensed and what aspects may affect the purchase
behavior. Herein, we have discussed some factors that
should be taken into account; i.e., use of the DDD,
stockpiling, refill lengths and changing dosages. Some
factors, such as regulations on refill times or timing of
holiday seasons, may vary in different countries. Still,
the same basic principles apply to drug use patterns
everywhere; e.g., stockpiling, holidays, and changing
doses over long periods of time. Prescription histories are
part of a modern human life, yet they cannot be accurately
and appropriately modeled with simple assumptions, such
as one DDD per day, 1 tablet per day or even by purchase
events every 90 days. Previously, most studies used fairly
simple models to estimate individual drug use.
We give below a short checklist that should be consid-
ered before proceeding with the actual data analysis in a
pharmacoepidemiology project with prescription register
data. The importance of different aspects varies by country,
patient group, ATC class and illness.
 Consider whether the assumption of fixed dose
(1 DDD per day or 1 tablet per day) is valid for
calculating exposure times. This may vary between
different drugs (ATC classes).
 Assess whether fixed refill times between purchase
times are valid. This may need to be checked by
ATC class.
 Do not underestimate stockpiling. Calculate estimates
for stockpiling and pay special attention to holiday
seasons.
 Use package information if available to make
estimates of refill times and dosages.
 Written dosage helps, but obtaining this data may
be laborious and may not take account on dosage
changes (often not written in the prescription if
persons has contacted physician by phone).
 Be aware of other sources of drugs (hospitals,
nursing homes, other countries, over the counter).
 Check hospital/nursing home/prison stays for
possible drug dispensing gaps in the register data.
Our examples are drawn from an older population
with Alzheimer disease, an incurable progressing disease.
This population have high rate of polypharmacy, high
number of hospital stays and often changing drug regi-
men. This population is selected as an example because
it shows how difficult it is to use simple fixed rules like
one DDD per day.
When transforming prescription drug purchases to
drug use periods personal dose, purchasing patterns and
other behavioral differences between patients should be
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